- The trend backdrop is active with a 10-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
FRX
TOR
Week ended 07 Aug 2026
Weekly Investor Report
Fennec Pharmaceuticals Inc. · Healthcare · Biotechnology
Latest close
16.02 CAD
15.7%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 36.6% above the Trend Line and sits at 99.1% of its 52-week range. The latest completed week returned 15.7%, after a 10.5% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers. The latest news-sentiment score is 52/100. Near-term considerations: price is close to its 52-week high; volume confirmation is below normal.
Setup score
61
out of 100
Latest Close
16.02 CAD
7 Aug 2026
1W Return
15.7%
latest completed week
4W Return
10.5%
short-term follow-through
12W Return
20.4%
quarterly tape
Trend Breadth
46.2%
24 of 52 weeks active
Volume Ratio
0.7x
vs 13-week average
- 2 reversal markers appear in the recent smart-money tape.
- Recent volatility is running well above the one-year baseline.
- Price is close to its 52-week high; watch for continuation or exhaustion.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
15.7%
Latest completed week; four-week move 10.5%.
Indicator stack
60/67
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
52/100
10 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 36.6% above the Trend Line and sits at 99.1% of its 52-week range. The latest completed week returned 15.7%, after a 10.5% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.9112-week average 0.51
12-week confirmation
Trend active10/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership10/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.91Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers
No recent accumulation markers. 2 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 10.5% over four weeks, 20.4% over 12 weeks, and 40.5% over one year. The current trend has remained active for 10 consecutive weeks.
Performance by holding period
Active trend streak10 weeks
Active weeks in one year24
Trend breadth46.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.96Latest activity-pressure read.
Pressure change-9.6%Four-week change in activity pressure.
Leadership21.72Latest relative-leadership reading.
RS change63.6%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 76%
Model confidence 71%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength12/100Blend of value, momentum, and quality. Underlying universe rank 89; rank 1 is best.
Value16/100Relative valuation strength. Underlying universe rank 85; rank 1 is best.
Quality10/100Profitability and accounting quality. Underlying universe rank 91; rank 1 is best.
Momentum69/100Medium-term price momentum. Underlying universe rank 32; rank 1 is best.
Growth19/100Revenue and earnings growth. Underlying universe rank 82; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 10.9x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -1.1% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 92.2% Gross profit retained from each unit of revenue.
- Operating margin
- -11.0% Operating profit retained from revenue.
- Free-cash-flow margin
- -11.3% Free cash flow generated from revenue.
- Return on invested capital
- -25.0% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -6.1% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -146.2% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 0/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -7.6% Net share repurchases relative to market value.
- Shareholder yield
- -7.6% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 3.1x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment52/100
Weighted news tone is neutral across 10 relevant articles.
1 positive · 9 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-0.5%Distance below the 52-week high.
13-week volatility12.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher11 of 2614 weeks finished lower.
Best week+37.9%Week of 15 May.
Worst week-17.4%Week of 27 Mar.
Latest week+15.7%Week of 7 Aug.
Shape of recent returns
Strong gains7
Modest gains4
Flat weeks1
Modest losses7
Sharp losses7
Recent vol12.2%13-week weekly-return volatility.
Base vol8.7%52-week weekly-return volatility.
Up/down split25/26Count of positive and negative weeks in the 52-week window.
Average skew7.2% / -4.9%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorCA Healthcare
4-week rank8 / 46
Group average0.0%
Trend breadth34.8%
Trend34.8%active weekly trend signals
MD47.8%positive activity pressure
RS23.9%positive relative leadership
Four-week leaders
IndustryCA Biotechnology
4-week rank2 / 11
Group average-4.4%
Trend breadth18.2%
Trend18.2%active weekly trend signals
MD54.5%positive activity pressure
RS27.3%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape58/100
Trend, activity pressure, participation, and risk combine to a 58/100 tape read.
Indicator analysis79/100Latest 12-week confirmation: trend 10/12, activity pressure 12/12, relative leadership 10/12.
Activity pressure 0.91; 2 reversal markers Factors24/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 89; Small Cap Core rank 90 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment52/100Weighted news tone is neutral across 10 relevant articles.
What's Going On With Fennec Pharmaceuticals Inc Stock Thursday? Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 16.02 CAD | 15.7% | 11.73 CAD | 10.64 CAD | 0.96 | 21.72 | 2.1K | On |
| 31 Jul 2026 | 13.85 CAD | -2.6% | 11.55 CAD | 10.61 CAD | 0.88 | 8.85 | 2.6K | On |
| 24 Jul 2026 | 14.22 CAD | 0.0% | 11.44 CAD | 10.59 CAD | 0.99 | 11.22 | 0 | On |
| 17 Jul 2026 | 14.22 CAD | -1.9% | 11.32 CAD | 10.57 CAD | 1.10 | 11.35 | 800 | On |
| 10 Jul 2026 | 14.50 CAD | -5.4% | 11.19 CAD | 10.55 CAD | 1.06 | 13.28 | 1.2K | On |
| 3 Jul 2026 | 15.32 CAD | 0.5% | 11.06 CAD | 10.53 CAD | 1.02 | 19.64 | 0 | On |
| 26 Jun 2026 | 15.24 CAD | 20.1% | 10.90 CAD | 10.51 CAD | 0.93 | 19.83 | 2.9K | On |
| 19 Jun 2026 | 12.69 CAD | 2.3% | 10.77 CAD | 10.49 CAD | 0.98 | -0.12 | 0 | On |
| 12 Jun 2026 | 12.40 CAD | -2.5% | 10.72 CAD | 10.49 CAD | 1.18 | -2.54 | 0 | On |
| 5 Jun 2026 | 12.72 CAD | -6.9% | 10.68 CAD | 10.49 CAD | 1.33 | 1.23 | 0 | On |
| 29 May 2026 | 13.67 CAD | -0.1% | 10.64 CAD | 10.48 CAD | 1.01 | 7.24 | 7.4K | Off |
| 22 May 2026 | 13.69 CAD | 2.9% | 10.57 CAD | 10.46 CAD | 0.54 | 8.12 | 8.4K | Off |
| 15 May 2026 | 13.31 CAD | 37.9% | 10.54 CAD | 10.44 CAD | 0.05 | 6.91 | 12.6K | Off |
| 8 May 2026 | 9.65 CAD | 8.8% | 10.48 CAD | 10.42 CAD | -0.45 | -22.93 | 2.0K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.